SYNTHESIS OF NON-GMP SMALL MOLECULES Base Year Increment 2

非 GMP 小分子的合成 基准年增量 2

• 批准号: 10936907
• 负责人: James D Talton
• 金额: $ 23.45万
• 依托单位: ALCHEM LABORATORIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-05 至 2023-06-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10936907
• 关键词: SYNTHESIS; NON; GMP; SMALL; MOLECULES

The Pharmaceutical Resources Branch (NCI/DCTD/DTP/PRB) requires a contractor that will provide services, personnel, equipment, and facilities as required to perform process development and synthesis of bulk materials under cGMP conditions. The quantity of a given material to be synthesized may range from multiple grams to multiple kilograms. These materials are required to be manufactured via well-defined and validated chemical processes, to be of high purity, and to be well-characterized. They are intended for use in formulation development, pharmacology and toxicology studies, and clinical trials. Major aspects of the contract work scope will include: (1) cGMP process development to transform laboratory-scale procedures to a robust and reproducible large-scale process; (2) synthesis of bulk chemicals/drugs on multi-gram to multikilogram scale as needed; (3) analysis for ensuring the purity, identity, and quality of the prepared compounds including QA/QC for the cGMP batches; and (4) additional studies such as solubility/stability as needed. Same as Base Year Increment 1.

药物资源处(NCI/DCTD/DTP/PRB)需要一名承包商，该承包商将提供所需的服务、人员、设备和设施，以执行cGMP条件下的工艺开发和大宗材料合成。要合成的给定材料的量可以从几克到几公斤不等。这些材料需要通过明确定义和有效的化学工艺制造，具有高纯度，并具有良好的特性。它们旨在用于配方开发、药理学和毒理学研究以及临床试验。合同工作范围的主要方面将包括：(1)cGMP工艺开发，以将实验室规模的程序转变为可靠和可重复的大规模工艺；(2)根据需要合成几克到几千克规模的散装化学品/药物；(3)分析以确保所制备化合物的纯度、特性和质量，包括cGMP批次的QA/QC；以及(4)根据需要进行其他研究，如溶解性/稳定性。与基准年增量1相同。